AstraZeneca PLC (AZN) on Monday announced that its LATIFY Phase III trial of ceralasertib in combination with Imfinzi did not meet the primary endpoint of overall survival (OS) compared with standard-of-care docetaxel in patients with locally advanced or metastatic non-small cell lung cancer (NSCLC).
The study focused on patients without actionable genomic alterations (AGAs) whose disease progressed following prior immunotherapy and platinum-based chemotherapy.
The company said that the combination was generally well tolerated, with a safety profile consistent with each medicine individually and no new safety concerns identified.
For comments and feedback contact: editorial@rttnews.com
Business News
May 01, 2026 15:54 ET Central banks dominated the economics news flow this week with almost all major ones announcing their latest policy decisions and many boosted expectations for a rate hike in June. In other news, several countries released the preliminary data for first quarter economic growth. In the U.S., comments by Fed Chair Jerome Powell were also in focus as his term ends this month.